Alzheimer's disease (AD) is a neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory and attention. Alzheimer’s disease is also characterised by neuropsychiatric symptoms like apathy, social withdrawal, disinhibition, agitation and psychosis. Later stage symptoms also include sleep disturbances and motor deficits like dystonia, akathisia and parkinsonian symptoms. AD is now the sixth leading cause of death in the United States, representing a significant unmet medical need.

At Transpharmation, our multi-faceted approach combines the use of naturally occurring deficits in aged animals along with pharmacological intervention to mimic aspects of the disease such as cognitive deficits, and sleep disruption. Furthermore, using our extensive biomarker platform we can profile translational disease markers such as TAU/phospho-TAU in both rodent and human tissue (via our CNS biobank) and assess the role of neuroinflammatory markers, such as cytokines, chemokines and microglia in AD disease pathology.

Examples of assays we offer:

  • •
    Biomarker analysis, including human tissue samples
  • •
    Delayed non-match to position task in aged rats
  • •
    Hyperlocomotion
  • •
    Temporal deficit and pharmacological-induced deficit novel object recognition test

Examples of models we offer:

  • •
    Aged canine model of late-onset Alzheimer's Disease
  • •
    Neuroinflammation modelling, in vivo (e.g. LPS) and ex-vivo (e.g. PBMCs)
  • •
    Scopolamine-induced model of reduced cholinergic tone
  • •
    Transgenic mouse models of tauopathy and amyloidopathy